source
- Priovant's Lisraya receives first FDA approval as oral therapy for dermatomyositisThe U.S. Food and Drug Administration has cleared Priovant Therapeutics' daily TYK2/JAK1 inhibitor tablet, marketed under the name Lisraya, for the treatment of dermatomyositis in adults. Lisraya…
- BioNTech stops Phase 2 colorectal cancer mRNA vaccine trial after futility findingsBioNTech announced that it is ending its Phase 2 study of a personalized mRNA vaccine for resected colorectal cancer after the trial failed to show the needed benefit. The news sent the company’s s…